- 英文名称1-((2R,3R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl)-3-(2-Methoxyethoxy)Tetrahydrofuran-2-yl)-5-Methylpyrimidine-2,4(1H,3H)-Dione
- 中文名称2'-O-(2-甲氧基乙基)-5-甲基尿苷
- IUPAC名称1-((2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-(2-methoxyethoxy)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione
- 其它别名Uridine, 2'-O-(2-Methoxyethyl)-5-Methyl-; 2'--O--Methoxyethyl-5-Methyluridine; 2'--O-Methoxyethyl-5-Methyluridine; 2'-O-Methoxyethyl-5-Methyluridine; 2'O-Methoxyethyl-5-Methyluridine; 9Q36I4D9Vb; Mf
- CAS编号163759-49-7
- MFCD编号:MFCD02682964
- FDA UNII编号:9Q36I4D9VB
- 分子式:C13H20N2O7
- 分子量:316.31
- 产品CID: 830334
- 产品分类有机原料→生命科学→核苷&核苷酸→2’-O-MOE修饰性核苷
- 相似结构搜索
- InChIKey: NEVQCHBUJFYGQO-DNRKLUKYSA-N
- InChI=1S/C13H20N2O7/c1-7-5-15(13(19)14-11(7)18)12-10(21-4-3-20-2)9(17)8(6-16)22-12/h5,8-10,12,16-17H,3-4,6H2,1-2H3,(H,14,18,19)/t8-,9-,10-,1…
- 计算化学: 氢键受体数8.0氢键供体数3可旋转键数6
相似化合物
55486-09-4 223777-15-9 1463-10-1上下游产品
CAS号22423-26-3 2,2'-脱水-5-甲基尿苷 | CAS号14983-42-7 三(2-甲氧基乙基)原硼酸酯 | CAS号109-86-4 乙二醇甲醚 | CAS号215713-37-4 2,2'-anhydro-1-... | CAS号168427-88-1 1-((2R,3R,4R,5R... | CAS号50-89-5 beta-胸苷 | CAS号553664-34-9 3'-O-Acetyl-2'-... | CAS号50-69-1 核糖 | CAS号168427-35-8 1-甲基-3,5-二-O-(2... | CAS号182496-01-1 5'-O-DMT-2'-O-M... | CAS号125016-87-7 1-methoxy-4-[me... | CAS号163759-50-0 5'-O-[双(4-甲氧基苯基...合成工艺路线路线简述
- 合成目标产物 2'-O-(2-Methoxyethyl)-5-Methyluridine 主要起始原料 2,2'-Anhydro-5-Methyluridine And 2-Methoxyethanol
- (文献来源)合成步骤主要原料 2,2'-Anhydro-5-Methyluridine 和 2-Methoxyethanol
1-[(2R,3R,4R,5R)-4-(2,4-Dichloro-Benzyloxy)-5-(2,4-Dichloro-Benzyloxymethyl)-3-(2-Methoxy-Ethoxy)-Tetrahydro-Furan-2-Yl]-5-Methyl-1H-Pyrimidine-2,4-Dione置于palladium On Activated Charcoal 氢气,Sodium Acetate体系中,用 甲醇 用作溶剂,45.0 °C,300.0 Kpa 条件下,以94%的收率获得2'-O-(2-甲氧基乙基)-5-甲基尿苷
参考文献:神经元祖刚族2'-O-烷基核糖核苷和本征结构的寡核苷酸
标题:神经元祖刚族2'-O-烷基核糖核苷和本征结构的寡核苷酸
摘要:新进入2个' ø烷基化的核糖核苷和2个'的属性ø烷基化的寡核糖核苷酸
Doi:10.1002/hlca.19950780219
海关参考信息
- 2905122000-异丙醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇
2905399001-1,3-丙二醇 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-6624294-B2
优先权日:1999-01-08
标 题:Regioselective synthesis of 2′-O-modified nucleosides
发明人:KAWASAKI ANDREW M; FRASER ALLISTER S; MANOHARAN MUTHIAH; COOK P DAN; PRAKASH THAZHA P
权利人:ISIS PHARMACEUTICALS INC
摘要:Methods for the regioselective alkylation at the 2'-hydroxy position over the 3'-hydroxy position of nucleosides and nucleoside analogs, forming 2'-O-ester modified compounds, are disclosed. Reduction and derivatization of the 2'-O-ester provides 2'-O-modified nucleosides and nucleoside analogs useful for the synthesis of oligomeric compounds having improved hybridization affinity and nuclease resistance.
专利号:US-6642367-B2
优先权日:1995-03-06
标 题:Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
发明人:COOK PHILLIP DAN; SANGHVI YOGESH S; SPRANKLE KELLY G; ROSS BRUCE S; GRIFFEY RICH H; SPRINGER ROBERT H
权利人:ISIS PHARMACEUTICALS INC
摘要:Oligonucleotide analogs are disclosed having pyrimidine monomeric sub-units therein that are modified at the 2′ and 5′ positions. Monomeric sub-units having these modifications may be further modified at the 2′ position. Improved processes for the synthesis of 2′-O-substituted pyrimidine nucleosides are also provided. The processes feature alkylation of a 2,2′-anhydropyrimidine nucleoside or a 2S,2′-anhydropyrimidine nucleoside with a weak nucleophile in the presence of a Lewis acid.
专利号:US-7339051-B2
优先权日:2003-04-28
标题 :Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
发明人:CROOKE STANLEY T; ECKER DAVID J; SAMPATH RANGARAJAN; FREIER SUSAN M; MASSIRE CHRISTIAN; HOFSTADLER STEVEN A; LOWERY KRISTIN SANNES; SWAYZE ERIC E; BAKER BRENDA F; BENNETT C FRANK
权利人:ISIS PHARMACEUTICALS INC
摘要:The present invention provides design and synthesis of oligomeric compounds and compositions that can be administered to reduce the activity of SARS virus in vivo or in vitro, to prevent or treat SARS virus-associated disease, to detect AARS virus, and to diagnose SARS virus-associated diseases.
专利号:US-7378516-B2
优先权日:1997-10-15
标题 :Synthesis of sulfurized oligonucleotides
发明人:COLE DOUGLAS L; RAVIKUMAR VASULINGA T; CHERUVALLATH ZACHARIA S
权利人:ISIS PHARMACEUTICALS INC
摘要:Methods for the formation of sulfurized oligonucleotides are provided. The methods allow for the formation of phosphorothioate linkages in the oligonucleotides or derivatives, without the need for complex solvent mixtures and repeated washing or solvent changes. Oligonucleotides having from about 8, and up to about 50, nucleotides can be sulfurized according to the methods of the invention with higher yields than have been previously reported.
专利号:US-6277982-B1
优先权日:1999-08-20
标题:Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates
发明人:FRASER ALLISTER S; MANOHARAN MUTHIAH; COOK PHILLIP DAN; JUNG MICHAEL E; KAWASAKI ANDREW M
权利人:ISIS PHARMACEUTICALS INC
摘要:Methods for the alkylation of alcohols, amines and thiols by the use of cyclic sulfates are disclosed. The alkylated sulfates formed are versatile intermediates which may be further elaborated by methods of the invention. In particular, methods for the alkylation of the 2′, 3′ or 5′-hydroxy position of nucleosides and nucleoside analogs with cyclic sulfates to form the 2′, 3′ or 5′-O-alkyl sulfate modified compounds are disclosed. Displacement of the 2′,3′ or 5′-O-sulfate with a nucleophile provides 2′, 3′ or 5′-O-modified nucleosides and nucleoside analogs useful for the synthesis of oligomeric compounds having improved hybridization affinity and nuclease resistance.
专利号:US-7002006-B2
优先权日:2003-02-12
标 题:Protection of nucleosides
发明人:SONG QUANLAI; ROSS BRUCE S
权利人:ISIS PHARMACEUTICALS INC
摘要:A process of manufacturing protected nucleosides comprises reacting a nucleoside with a protecting reagent in the presence of a regioselective activator to produce a regioselectively protected nucleoside. In some embodiments of the inventive method, an optionally substituted trityl or optionally substituted pixyl group is selectively added to the 5'-O-position of a nucleoside in the presence of lutidine as activator or activator/solvent. The inventive method results in improved selectivity of the 5'-O-position over the 3'-O-position, thereby improving overall product yield and purity, and permitting simplified purification protocols, in some cases obviating the need for chromatography to produce a purified protected nucleoside suitable for automated synthesis of oligonucleotides, such as primers, probes and antisense molecules.